Cardiol Therapeutics Shareholders: Ownership Structure, Brands, and Acquisition History
Last updated: August-2026Ownership Structure
Stakes approximate based on latest filings.
Ownership Analysis
Public shareholders own the company, while the board must challenge management on trial design, financing timing and the threshold for continuing each program. This is the central issue in control and governance because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.David Elsley leads the business and Timothy Garnett chairs or represents the governing board. The owner field records Public Shareholders at 100%, so formal percentages must be read beside voting rights and contractual authority. The practical test is whether directors challenge management when strategic ambition conflicts with owner returns. Disclosure should make relevant tradeoffs visible rather than forcing investors to infer them from headline results.The downside case is concrete: clinical failure, safety findings, enrollment delays, regulatory demands, manufacturing scale-up, patent limits and repeated equity dilution can erase value. I would not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to the board. A credible plan must specify triggers for reducing spending, leverage or complexity.At an equity value of $218.46 million, the market prices meaningful trial success while assigning no value to current commercial cash flow. A governance premium is earned only when independent oversight reduces agency risk and protects capital through a cycle. Investors should compare implied expectations with achievable cash returns and avoid paying for targets that have not survived a full operating cycle. Scenario analysis should include weaker demand and higher funding costs.I would tie executive rewards to per-share or owner value, balance-sheet resilience and clearly measured strategic outcomes. I would stage spending against prespecified clinical evidence, preserve at least one major financing window and avoid broadening the pipeline before pivotal risk declines. My view is that Cardiol Therapeutics deserves a premium only when management demonstrates measurable value creation after all operating, financing and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Direct Owners
Institutional Shareholders
Shareholder Analysis
Specialist healthcare funds can improve technical scrutiny, but a concentrated small-cap register can also amplify volatility during clinical readouts. This is the central issue in shareholder composition and capital-market behavior because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The institutional register lists Armistice Capital, Sabby Management, The Vanguard Group, Geode Capital Management at 9.9%, 4.9%, 1.7%, 1.4%. These holders influence elections, liquidity or private control, but they do not guarantee a common view on strategy or risk. The practical test is whether directors challenge management when strategic ambition conflicts with owner returns. Disclosure should make relevant tradeoffs visible rather than forcing investors to infer them from headline results.The downside case is concrete: clinical failure, safety findings, enrollment delays, regulatory demands, manufacturing scale-up, patent limits and repeated equity dilution can erase value. I would not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to the board. A credible plan must specify triggers for reducing spending, leverage or complexity.At an equity value of $218.46 million, the market prices meaningful trial success while assigning no value to current commercial cash flow. Stable institutions or sponsors can reduce financing uncertainty, but concentration cannot substitute for durable operating results or engaged directors. Investors should compare implied expectations with achievable cash returns and avoid paying for targets that have not survived a full operating cycle. Scenario analysis should include weaker demand and higher funding costs.I would expect major holders to press for transparent capital priorities, credible downside planning and disciplined compensation. I would stage spending against prespecified clinical evidence, preserve at least one major financing window and avoid broadening the pipeline before pivotal risk declines. My view is that Cardiol Therapeutics deserves a premium only when management demonstrates measurable value creation after all operating, financing and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Brands, Subsidiaries & Companies Owned
| Name | Type | Description |
|---|
Portfolio Analysis
CardiolRx carries most of the corporate value, while program names help distinguish indications without creating independent consumer franchises. This is the central issue in brand and portfolio strategy because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The portfolio includes CardiolRx, CRD-38, MAVERIC and ARCHER. Each identity should have a defined customer promise and economic role, with shared capabilities producing measurable benefits rather than administrative complexity. The practical test is whether directors challenge management when strategic ambition conflicts with owner returns. Disclosure should make relevant tradeoffs visible rather than forcing investors to infer them from headline results.The downside case is concrete: clinical failure, safety findings, enrollment delays, regulatory demands, manufacturing scale-up, patent limits and repeated equity dilution can erase value. I would not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to the board. A credible plan must specify triggers for reducing spending, leverage or complexity.At an equity value of $218.46 million, the market prices meaningful trial success while assigning no value to current commercial cash flow. A portfolio premium requires evidence that customer trust, technical know-how or distribution produces stronger retention and margins. Investors should compare implied expectations with achievable cash returns and avoid paying for targets that have not survived a full operating cycle. Scenario analysis should include weaker demand and higher funding costs.I would invest behind identities with the strongest incremental returns and simplify offerings that do not reinforce customer advantage. I would stage spending against prespecified clinical evidence, preserve at least one major financing window and avoid broadening the pipeline before pivotal risk declines. My view is that Cardiol Therapeutics deserves a premium only when management demonstrates measurable value creation after all operating, financing and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Market Share & Competitors
Bubble size reflects relative market share.
| Company | Market Share | Revenue | Key Strength |
|---|
Competitive Analysis
Cardiol competes for patients, investigators and capital against better-funded drug developers with broader pipelines and commercial infrastructure. This is the central issue in competitive position and valuation because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The current performance base is no product revenue in 2025, an 18-person workforce and a clinical portfolio centered on CardiolRx, CRD-38, MAVERIC and ARCHER. Competitive strength should be tested through pricing, retention, market share, unit economics and return on invested capital rather than broad claims about addressable markets. The practical test is whether directors challenge management when strategic ambition conflicts with owner returns. Disclosure should make relevant tradeoffs visible rather than forcing investors to infer them from headline results.The downside case is concrete: clinical failure, safety findings, enrollment delays, regulatory demands, manufacturing scale-up, patent limits and repeated equity dilution can erase value. I would not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to the board. A credible plan must specify triggers for reducing spending, leverage or complexity.At an equity value of $218.46 million, the market prices meaningful trial success while assigning no value to current commercial cash flow. A competitive premium should follow sustainable cash economics and reinvestment opportunity, not one favorable period or a temporary shortage. Investors should compare implied expectations with achievable cash returns and avoid paying for targets that have not survived a full operating cycle. Scenario analysis should include weaker demand and higher funding costs.I would track leading indicators of pricing power and retention before assuming any cyclical improvement is permanent. I would stage spending against prespecified clinical evidence, preserve at least one major financing window and avoid broadening the pipeline before pivotal risk declines. My view is that Cardiol Therapeutics deserves a premium only when management demonstrates measurable value creation after all operating, financing and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Acquisitions
Bubble size reflects relative deal value.
| Company Acquired | Deal Value | Year | Description |
|---|
Acquisitions Analysis
The absence of corporate acquisitions is appropriate because Cardiol's scarce capital should resolve clinical risk before adding outside assets. This is the central issue in acquisition discipline and integration because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The transaction record matters because cardiol funds trials through equity offerings and cash reserves, making dilution, study pacing and regulatory evidence the central allocation decisions. Management should publish post-deal scorecards comparing promised economics with retention, margins, cash conversion and financing costs. The practical test is whether directors challenge management when strategic ambition conflicts with owner returns. Disclosure should make relevant tradeoffs visible rather than forcing investors to infer them from headline results.The downside case is concrete: clinical failure, safety findings, enrollment delays, regulatory demands, manufacturing scale-up, patent limits and repeated equity dilution can erase value. I would not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to the board. A credible plan must specify triggers for reducing spending, leverage or complexity.At an equity value of $218.46 million, the market prices meaningful trial success while assigning no value to current commercial cash flow. Deal-driven growth warrants a premium only when acquired cash flows exceed financing, integration and opportunity costs under conservative assumptions. Investors should compare implied expectations with achievable cash returns and avoid paying for targets that have not survived a full operating cycle. Scenario analysis should include weaker demand and higher funding costs.I would require a conservative base case, an explicit failure case and a formal post-close review before approving another material transaction. I would stage spending against prespecified clinical evidence, preserve at least one major financing window and avoid broadening the pipeline before pivotal risk declines. My view is that Cardiol Therapeutics deserves a premium only when management demonstrates measurable value creation after all operating, financing and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Acquisition Timeline
Merger & Spin-off History
Merger & Spin-off Analysis
Cardiol has avoided merger complexity, so investors can focus on clinical evidence and dilution rather than purchase accounting or integration. This is the central issue in merger, spinoff and structural history because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.Cardiol Therapeutics has remained an independent clinical-stage company and has not completed a material merger or corporate acquisition. Its value has been built through intellectual property, formulation work, regulatory development and clinical trials. Equity issuance, rather than combinations, has been the main structural source of funding and ownership change. Today's segments, leverage and strategic choices are direct consequences of those structural decisions. The practical test is whether directors challenge management when strategic ambition conflicts with owner returns. Disclosure should make relevant tradeoffs visible rather than forcing investors to infer them from headline results.The downside case is concrete: clinical failure, safety findings, enrollment delays, regulatory demands, manufacturing scale-up, patent limits and repeated equity dilution can erase value. I would not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to the board. A credible plan must specify triggers for reducing spending, leverage or complexity.At an equity value of $218.46 million, the market prices meaningful trial success while assigning no value to current commercial cash flow. Structural change creates value only when accountability, focus or cash generation improves after tax, financing and integration costs. Investors should compare implied expectations with achievable cash returns and avoid paying for targets that have not survived a full operating cycle. Scenario analysis should include weaker demand and higher funding costs.I would support another structural move only if quantified benefits exceed integration cost, leverage and lost flexibility. I would stage spending against prespecified clinical evidence, preserve at least one major financing window and avoid broadening the pipeline before pivotal risk declines. My view is that Cardiol Therapeutics deserves a premium only when management demonstrates measurable value creation after all operating, financing and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Ownership History
Ownership History Analysis
The ownership history is primarily a sequence of equity financings, making value per share more important than headline pipeline expansion. This is the central issue in ownership and strategic evolution because percentages alone do not reveal who determines risk appetite, investment pacing or portfolio priorities. Governance should be judged by decisions and outcomes.The defining arc is a Canadian clinical-stage company using public equity to advance a concentrated cardiovascular inflammation and fibrosis pipeline. Heritage supports credibility only when its best operating lessons remain embedded in incentives, succession and capital discipline. The practical test is whether directors challenge management when strategic ambition conflicts with owner returns. Disclosure should make relevant tradeoffs visible rather than forcing investors to infer them from headline results.The downside case is concrete: clinical failure, safety findings, enrollment delays, regulatory demands, manufacturing scale-up, patent limits and repeated equity dilution can erase value. I would not dismiss that exposure as temporary because it can change normalized margins, funding costs and the options available to the board. A credible plan must specify triggers for reducing spending, leverage or complexity.At an equity value of $218.46 million, the market prices meaningful trial success while assigning no value to current commercial cash flow. Historical success informs judgment but cannot be capitalized indefinitely when leadership, technology or industry structure changes. Investors should compare implied expectations with achievable cash returns and avoid paying for targets that have not survived a full operating cycle. Scenario analysis should include weaker demand and higher funding costs.I would preserve capabilities that created the franchise while discarding legacy practices that no longer earn adequate returns. I would stage spending against prespecified clinical evidence, preserve at least one major financing window and avoid broadening the pipeline before pivotal risk declines. My view is that Cardiol Therapeutics deserves a premium only when management demonstrates measurable value creation after all operating, financing and integration costs. That standard keeps the analysis focused on owner outcomes rather than corporate activity.
Ownership Explained
Cardiol Therapeutics is publicly traded and it has no corporate parent. David Elsley leads the business and Timothy Garnett chairs or represents the governing board. Ownership percentages must be read with voting rights, merger agreements and contractual authority.The operating model is a late-stage life-sciences company developing anti-inflammatory and anti-fibrotic therapies for pericarditis, myocarditis and heart failure. Important owned identities include CardiolRx, CRD-38, MAVERIC and ARCHER. These businesses share capital, risk oversight and strategic direction even when customer relationships remain attached to product, local or specialist names.The latest annual record includes no product revenue in 2025, an 18-person workforce and a clinical portfolio centered on CardiolRx, CRD-38, MAVERIC and ARCHER. Full-year figures are the cleanest scale reference because quarters can be distorted by seasonality, transaction timing, purchase accounting or volatile end markets. Investors should still reconcile revenue with free cash flow and balance-sheet change.Cardiol funds trials through equity offerings and cash reserves, making dilution, study pacing and regulatory evidence the central allocation decisions. In my view, the decisive ownership question is how management and the governing board allocate cash and strategic attention. A shareholder list is descriptive, while capital-allocation outcomes reveal who benefits from control.
Public ownership shapes disclosure, financing flexibility and management accountability at Cardiol Therapeutics. The governing board must convert control and access to capital into durable value and should not treat revenue growth, asset count or transaction volume as ends in themselves.clinical failure, safety findings, enrollment delays, regulatory demands, manufacturing scale-up, patent limits and repeated equity dilution can erase value. Owners and stakeholders therefore need operating indicators that reveal whether the franchise is strengthening before reported earnings fully reflect the change. Balance-sheet resilience is part of ownership quality because it preserves strategic choice during stress.At an equity value of $218.46 million, the market prices meaningful trial success while assigning no value to current commercial cash flow. This context raises the hurdle for every acquisition, repurchase, development program or restructuring decision. Management should compare each use of funds against debt reduction and the value of retaining liquidity.I would stage spending against prespecified clinical evidence, preserve at least one major financing window and avoid broadening the pipeline before pivotal risk declines. That discipline is what ownership means in practice for investors, employees, customers and creditors. The enterprise deserves confidence only when governance converts control into transparent, repeatable cash returns.